research Bioavailability File: Bicalutamide
Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Combined hormonal contraception and venous thromboembolism
Birth control pills increase the risk of blood clots, especially within the first year and with certain types.
research Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
Brepocitinib improves cicatricial alopecia and reduces key immune markers.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Bicalutamide
research β-sitosterol in Yijing Hugui decoction prevents cyclophosphamide-induced premature ovarian insufficiency via the AKT1/Nrf2 pathway
research Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial
Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.
research EFFECTS OF A LOW‐DOSE DESOGESTREL‐ETHINYLESTRADIOL COMBINATION ON HIRSUTISM, ANDROGENS AND SEX HORMONE BINDING GLOBULIN IN WOMEN WITH A POLYCYSTIC OVARY SYNDROME
Low-dose oral contraceptives reduced hair growth and testosterone levels in women with polycystic ovary syndrome.
research Changes in the serum metabolomics of polycystic ovary syndrome before and after compound oral contraceptive treatment
COC treatment improves hormone and metabolic levels in PCOS patients.
research Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
research Clinical effectiveness of ethinylestradiol-cyproterone acetate and raloxifene combination therapy in polycystic ovary syndrome-associated infertility
The combination therapy effectively treats infertility in PCOS without major side effects.
research Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case–control analysis using German claims data
Some birth control pills increase young women's risk of blood clots more than others.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research Результаты применения комбинированных оральных контрацептивов с дроспиреноном и финастерида у женщин с синдромом поликистозных яичников без метаболических нарушений
Both finasteride and drospirenone treatments improved symptoms and increased pregnancy rates in women with polycystic ovary syndrome.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Finasteride/flibanserin
research Clobetasol/minoxidil
research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.
research Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport
Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
research [Clinical findings with a low-dosed antiandrogene (cyproteronacetate) and aethinyloestradiol women with virilising symptoms (author's transl)].
The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
research Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta‐Analysis
Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
research Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
research Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism
The treatment temporarily improved symptoms of hyperandrogenism in adolescents.